Full Press Release Details
DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021
Universal Registration Document
DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission (SEC) and the filing of its
2021 Universal Registration Document (URD) for the year ended December 31, 2021 with the French market authority Autorit des March s Financiers (AMF).
These documents can be accessed on the Investors section of the Company s website at
www.dbv-technologies.com. In addition, the Universal Registration Document is available on the AMF s website at www.amf-france.org and the Form 10-K is available on the SEC s website at www.sec.gov.
Printed copies of both documents are available, free
of charge, at the Company s headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.
About DBV Technologies
DBV Technologies is developing
Viaskin , an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT , DBV s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product
candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and
North American operations in Summit, NJ. The Company s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).